Opthea (OPT) News Today $3.41 +0.23 (+7.23%) As of 04/14/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Regal: Don’t catch the falling knife, wait for it to stick in the floorApril 16 at 1:28 AM | msn.comBELL POTTER SECURITIES Downgrades Opthea (CKDXF)April 9, 2025 | msn.comBELL POTTER SECURITIES Downgrades Opthea Limited - Depositary Receipt () (OPT)April 9, 2025 | msn.comASX drops as US jumbo China tariff takes effectApril 9, 2025 | afr.comShort Interest in Opthea Limited (NASDAQ:OPT) Expands By 20.7%Opthea Limited (NASDAQ:OPT - Get Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 522,200 shares, a growth of 20.7% from the February 28th total of 432,800 shares. Based on an average daily trading volume, of 31,700 shares, the short-interest ratio is presently 16.5 days. Currently, 0.4% of the company's stock are sold short.April 4, 2025 | marketbeat.comOpthea Limited (CKDXF) was downgraded to a Sell Rating at Bell PotterApril 3, 2025 | markets.businessinsider.comPhil King’s Regal writes Opthea to zero and backs off risky betsApril 2, 2025 | afr.comOpthea Ends Development of Sozinibercept in Wet AMDMarch 31, 2025 | marketwatch.comOpthea terminates COAST trial, announces ShORe trial misses endpointMarch 31, 2025 | markets.businessinsider.comOpthea Announces Decision to Discontinue Wet AMD TrialsMarch 31, 2025 | globenewswire.comOpthea Limited’s Securities Suspended Due to Financial ConcernsMarch 30, 2025 | tipranks.comJPMorgan Chase Acquires Substantial Stake in Opthea LimitedMarch 30, 2025 | tipranks.comResearch Analysts Issue Forecasts for Opthea FY2025 EarningsOpthea Limited (NASDAQ:OPT - Free Report) - Stock analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Opthea in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst M. Caufield now expects that the company will post earningsMarch 28, 2025 | marketbeat.comFY2025 EPS Estimates for Opthea Decreased by Leerink PartnrsOpthea Limited (NASDAQ:OPT - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2025 earnings estimates for shares of Opthea in a research report issued to clients and investors on Monday, March 24th. Leerink Partnrs analyst M. Goodman now expects that the company will post earMarch 28, 2025 | marketbeat.comHotCopper Highlights for Week 13 – Opthea, Reject Shop, Bellevue & more!March 28, 2025 | msn.comThe clinical trial result from hell has biotech investors on edgeMarch 28, 2025 | afr.comOpthea Limited (NASDAQ:OPT) Receives Consensus Rating of "Hold" from BrokeragesShares of Opthea Limited (NASDAQ:OPT - Get Free Report) have been given an average rating of "Hold" by the six analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and oneMarch 27, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Downgraded by Leerink Partnrs to HoldLeerink Partnrs cut shares of Opthea from a "strong-buy" rating to a "hold" rating in a research note on Monday.March 27, 2025 | marketbeat.comPengana freezes fund redemptions as it braces for big Opthea lossMarch 27, 2025 | afr.comOpthea (NASDAQ:OPT) Downgraded to "Neutral" Rating by HC WainwrightHC Wainwright lowered Opthea from a "buy" rating to a "neutral" rating and set a $2.00 price target on the stock. in a research note on Tuesday.March 26, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Stock Rating Lowered by Leerink PartnersLeerink Partners lowered Opthea from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $12.00 to $1.00 in a research report on Tuesday.March 26, 2025 | marketbeat.comOpthea's (OPT) Underperform Rating Reaffirmed at Jefferies Financial GroupJefferies Financial Group reissued an "underperform" rating and set a $1.00 price target on shares of Opthea in a research note on Tuesday.March 26, 2025 | marketbeat.comOpthea cut to Market Perform at Leerink on failed sozinibercept trialMarch 26, 2025 | markets.businessinsider.comOpthea double downgraded to Underperform from Buy at JefferiesMarch 26, 2025 | markets.businessinsider.comHearts and Minds Investments Updates on Opthea Limited Portfolio ImpactMarch 25, 2025 | tipranks.comOppenheimer Downgrades Opthea (NASDAQ:OPT) to Market PerformOppenheimer lowered Opthea from an "outperform" rating to a "market perform" rating in a report on Monday.March 25, 2025 | marketbeat.comHold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial FailureMarch 25, 2025 | tipranks.comOpthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial UncertaintyMarch 25, 2025 | tipranks.comOpthea COAST trial misses primary endpoint, enters talks with DFA InvestorsMarch 24, 2025 | markets.businessinsider.comAmid fears of collapse, what's happening with Opthea ASX shares today?March 24, 2025 | msn.comMonday’s HotCopper Trends: Opthea strife, Memphasys best-in-class results | March 21, 2025March 24, 2025 | msn.comOpthea's Phase 3 trial results fail to help patients, future of company at riskMarch 24, 2025 | msn.comOpthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial UncertaintyMarch 24, 2025 | benzinga.comOpthea Announces COAST Phase 3 Trial Topline ResultsMarch 24, 2025 | globenewswire.comOpthea Limited Suspends Trading Pending Clinical Trial ResultsMarch 18, 2025 | tipranks.comHealth Check: Awaiting key announcements, these biotechs could use some Irish luckMarch 16, 2025 | msn.comOpthea Limited Initiates Trading Halt Ahead of Key Clinical Trial ResultsMarch 16, 2025 | tipranks.comOpthea (NASDAQ:OPT) Shares Gap Up - Time to Buy?Opthea (NASDAQ:OPT) Shares Gap Up - Still a Buy?March 15, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Trading 3.6% Higher - Here's What HappenedOpthea (NASDAQ:OPT) Stock Price Up 3.6% - Here's What HappenedMarch 14, 2025 | marketbeat.comJPMorgan Acquires Substantial Stake in Opthea LimitedMarch 14, 2025 | tipranks.comOpthea Limited Announces Quotation of New Securities on ASXMarch 14, 2025 | tipranks.comOpthea Limited Announces New Quotation of Securities on ASXMarch 14, 2025 | tipranks.comOpthea Limited Announces New Securities Quotation on ASXMarch 10, 2025 | tipranks.comOpthea Limited Announces New Securities Quotation on ASXMarch 10, 2025 | tipranks.comOpthea Limited (OPT): Among the Best Australian Stocks to Buy According to BillionairesMarch 10, 2025 | finance.yahoo.comOpthea (NASDAQ:OPT) Sees Unusually-High Trading Volume - Should You Buy?Opthea (NASDAQ:OPT) Sees Large Volume Increase - Time to Buy?March 8, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Shares Gap Up - Still a Buy?Opthea (NASDAQ:OPT) Shares Gap Up - Here's What HappenedMarch 6, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Trading Down 10.5% - Should You Sell?Opthea (NASDAQ:OPT) Trading Down 10.5% - Here's What HappenedMarch 5, 2025 | marketbeat.comOpthea (NASDAQ:OPT) Trading Up 4.2% - Here's WhyOpthea (NASDAQ:OPT) Stock Price Up 4.2% - Still a Buy?March 4, 2025 | marketbeat.comOpthea Announces Phase 2b Wet AMD PublicationMarch 3, 2025 | globenewswire.com Remove Ads Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address OPT Media Mentions By Week OPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPT News Sentiment▼0.550.78▲Average Medical News Sentiment OPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPT Articles This Week▼43▲OPT Articles Average Week Remove Ads Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VCEL News MIRM News SDGR News DNLI News MTSR News BHVN News BLTE News NAMS News TARS News JANX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OPT Stock Free OPT Stock Alerts